Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Antihistamines Equally Efficacious, Safer Than OTCs - Blue Cross

This article was originally published in The Tan Sheet

Executive Summary

Data show that second-generation, low- and non-sedating antihistamines such as cetirizine (Pfizer's Zyrtec), loratadine (Schering-Plough's Claritin) and fexofenadine (Aventis' Allegra) are equally efficacious and less toxic than first-generation OTC antihistamines, according to an evidence report filed with FDA.

You may also be interested in...



Antihistamine OTC Switch Petition Slated For NDAC Debate May 11

FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.

Antihistamine OTC Switch Petition Slated For NDAC Debate May 11

FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.

Antihistamine OTC Switch Petition Slated For NDAC Debate May 11

FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel